(Q46429390)

22 December 2017

title

Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis (English)

1 reference

22 December 2017

0 references

1

1 reference

22 December 2017

Jack Cuzick

2

object named as

Jack Cuzick

1 reference

22 December 2017

Aman U Buzdar

7

object named as

Aman U Buzdar

1 reference

22 December 2017

author name string

Francisco Sapunar

3

1 reference

22 December 2017

Richard Eastell

4

1 reference

22 December 2017

John F Forbes

5

1 reference

22 December 2017

Angelo R Bianco

6

1 reference

22 December 2017

ATAC Trialists' Group

8

1 reference

22 December 2017

publication date

12 August 2008

1 reference

22 December 2017

Lancet Oncology Commission

published in

1 reference

22 December 2017

volume

9

1 reference

22 December 2017

issue

9

1 reference

22 December 2017

page(s)

866-872

1 reference

22 December 2017

The prevalence and characteristics of fibromyalgia in the general population.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

The prevalence of symptoms possibly related to the climacteric in pre- and postmenopausal women in Linköping, Sweden.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Immune responses and bone loss: the estrogen connection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Phase II trial of a doxorubicin/docetaxel doublet for locally advanced and metastatic breast cancer: results from national surgical adjuvant breast and bowel project trial BP-57.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Low biologic aggressiveness in breast cancer in women using hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Prognosis of breast cancers detected in women receiving hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: a long-term prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Hormone dependency of breast tumours developing in the Guernsey Cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Individual risk factors for hip osteoarthritis: obesity, hip injury, and physical activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Five-year update of an expanded phase II study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Historical control study of paclitaxel-carboplatin (TJ) versus conventional platinum-based chemotherapy (CAP) for epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

Tolerance of adjuvant letrozole outside of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970182-7

7 January 2021

10.1016/S1470-2045(08)70182-7

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017